Collegium Pharmaceutical’s (COLL) Buy Rating Reiterated at HC Wainwright

Collegium Pharmaceutical (NASDAQ:COLL)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports. They presently have a $50.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright’s price objective indicates a potential upside of 49.97% from the stock’s current price.

Several other equities research analysts have also recently weighed in on COLL. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 23rd. Piper Sandler reaffirmed a “neutral” rating and issued a $37.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, October 11th. Finally, Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target for the company in a research report on Friday. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $43.80.

Collegium Pharmaceutical Stock Up 14.4 %

COLL stock opened at $33.34 on Friday. Collegium Pharmaceutical has a fifty-two week low of $28.39 and a fifty-two week high of $42.29. The company has a market capitalization of $1.08 billion, a price-to-earnings ratio of 14.37 and a beta of 0.82. The business’s 50 day moving average price is $30.57 and its two-hundred day moving average price is $34.04. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97.

Hedge Funds Weigh In On Collegium Pharmaceutical

Several large investors have recently modified their holdings of COLL. GAMMA Investing LLC increased its stake in Collegium Pharmaceutical by 124.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock valued at $55,000 after purchasing an additional 792 shares in the last quarter. CWM LLC grew its holdings in shares of Collegium Pharmaceutical by 97.5% during the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock valued at $58,000 after buying an additional 736 shares during the last quarter. TD Private Client Wealth LLC grew its holdings in shares of Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after buying an additional 483 shares during the last quarter. Virtus Fund Advisers LLC bought a new stake in shares of Collegium Pharmaceutical during the third quarter valued at approximately $72,000. Finally, AXA S.A. purchased a new position in Collegium Pharmaceutical in the 2nd quarter worth approximately $209,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.